News New two-year preclinical program for EHMT1 gene replacement Katerina Tzimourta, June 14, 2026August 21, 2026 IDefine and UT Southwestern announced a collaboration of approximately $310,000 to study the feasibility and safety of EHMT1 gene replacement targeting the central nervous system. The program is preclinical: there is no human trial or efficacy result.